Technivie - Hepatitis C Drug Information

Technivie (ombitasvir + paritaprevir + ritonavir) inogadziriswa-inonzi inoshandiswa mushonga unoshandiswa mukurapwa kwehutachiona hwehupachipatara hweH hepatitis C (HCV) . Ivatatu vatatu vanosanganisira Technivie vanobatanidzwawo muviri-pill HCV therapy, Viekira Pak .

Technivie yakagamuchirwa musi waJuly 24, 2015 neU.S. Food and Drug Administration (FDA) iyo inoshandiswa kune vanhu vakuru kwemakore gumi nemana kana kupfuura neHCV genotype 4 utachiona (GT4) pasina cirrhosis .

Technivie ndiyo yekutanga, yose-inotaura, inopferon-isina hutachiona hweHCV yevarwere GT4 chronic HCV chirwere, chizvarwa chinowanzoonekwa chakaoma kurapa.

Technivie yakaudzwa kuti ine chirwere chekurapa kwe100% yekare isina kutorwa ("chirongwa naïve") varwere muPekutanga IIb kutongwa kunoitwa kubva paAugust 12, 2012 kusvika kuNovember 19, 2013.

Dosage

Mahwendefa maviri (12.5mg ombitasvir, 75mg paritaprevir, 50mg ritonavir) inotorwa zuva nezuva nekudya kunze kwekudiwa kwemafuta akawanda kana caloric kudya. Technivie mahwendefa akapfava, oblong uye mafirimu-akafukidzwa, ne "AV1" yakaiswa pamativi ose.

Kunyora Zvikurudzira

Technivie inorayirwa pamusoro pechikoro chemavhiki gumi nemaviri pamwe chete ne ribavirin (mushonga unoshandiswa kudzivisa utachiona hweRNA synthesis). Nhamba yakakurudzirwa ye ribavirin inobva pauremu, sezvinotevera:

Kirasi yemasvondo gumi nemaviri e Technivie inogona kufungwa nezvekurapa naïve murwere asingagoni kubvumira ribavirin.

Nharaunda Dzakabatana

Maitiro akawandisa anowanzobatanidzwa nekushandiswa kwe Technivie (inowanikwa nevanenge 7% varwere) ndei:

Contraindicated Mishonga

Mishonga inotevera inofanirawo kusatorwa kana uchishandisa Technivie:

Contraindications nekufungisisa

Technivie haina kukurudzirwa kune varwere vane uwandu hwenhepatic impairment (Child-Pugh chikwata B) uye zvinopesana nevarwere vane kuora mwoyo kwakanyanya (Child-Pugh mhinduro C).

Technivie inopindirana kuti ishandiswe kune varwere vane hunozivikanwa hypersensitivity kune ritonavir (kureva, avo vakawana Stevens-Johnson Syndrome kana chepidermal necrolysis).

Kunyange zvazvo Technivie pachayo isiri iyo inopesana nemashandisirwo ekudzivirira, kusanganiswa kweTynivirin uye ribavirin uye hakufaniri kushandiswa mumadzimai ane pamuviri kana varume avo vane shamwari dzevakadzi vane pamuviri. Mukutaura kwekuyamwisa, pakanga pasina zviitiko zvekusagona kushandiswa kwemazwi ekudzidzira muzviongorori zvemhuka; nyanzvi yekukurukurirana inokurudzirwa kuti ikurukure maitiro anobatsira nemigumisiro yakaipa yekuyamwisa panguva iyo paChnivie.

Kunobva:

US Food and Drug Administration (FDA). "FDA inobvumira Technivie kurapwa kwechirwere chekushaya hepatitis C gumbo 4." Silver Spring, Maryland; nyaya yekubudiswa yakabudiswa musi waJuly 24, 2015.

Hézode, C .; Asselah, T .; Reddy, R .; et al. "Ombitasvir pamwe neparitaprevir uye ritonavir pamwe chete kana kuti pasina ribavirin mukurapa-naive uye kurapwa-vane ruzivo vane genotype 4 chirwere chepachirwere chetachipatara chepachipatara C (PEARL-I): chirongwa chisinganzwisisiki. Lancet. June 20, 2015; 384 (9986): 2502-2509.